SCHEMBL179285

SCHEMBL179285

Cc1ccnc(C(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.52
CCR1 P32246 1/20 0.52
CCR5 P51681 1/20 0.52
CCR8 P51685 1/20 0.52
LMNA P02545 6/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NOS3 P29474 1/20 0.48
NOS1 P29475 1/20 0.48
NOS2 P35228 1/20 0.48
ALDH1A1 P00352 5/20 0.44
PLAU P00749 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.38
PRKCI P41743 1/20 0.38
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508711 1.00 UHRF1 (0.52) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL7002997 0.85 UHRF1 (0.53) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL16094048 0.84 UHRF1 (0.50) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL31032211 0.84 UHRF1 (0.50) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL8154445 0.82 KDM4E (0.50) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL14297355 0.82 UHRF1 (0.48) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL129055 0.82 UHRF1 (0.48) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL29608524 0.82 UHRF1 (0.48) UHRF1CCR1CCR5CCR8LMNA
SCHEMBL132321 0.79 LOXL2 (0.52) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL30262293 0.79 LOXL2 (0.52) UHRF1CCR1CCR5CCR8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791279-B2 Process for preparing taxoids from baccatin derivatives using lewis acid catalyst YUNG SHIN PHARM. IND. CO., LTD. (TW) 2014-07-29 US claimed
US-20120149925-A1 PROCESS FOR PREPARING TAXOIDS FROM BACCATIN DERIVATIVES USING LEWIS ACID CATALYST YUNG SHIN PHARM. IND. CO., LTD. (TW) 2012-06-14 US claimed
EP-1172878-B1 Non-aqueous electrolytic solution and secondary battery containing same MITSUBISHI CHEM CORP (JP) 2011-06-22 EP claimed
US-7595370-B2 Reacting cyclosiloxane with unsaturated organosilylated carboxylate monomer or copolymer under presence of catalyst; antifouling paints, marine systems PPG B.V. (NL) 2009-09-29 US claimed
US-20060142516-A1 Process for the preparation of polyorganosilylated carboxylate monomers or polymers thereof SIGMA COATINGS B.V. (NL) 2006-06-29 US claimed
EP-1539861-A1 PROCESS FOR THE PREPARATION OF POLYORGANOSILYLATED CARBOXYLATE MONOMERS OR POLYMERS THEREOF Sigmakalon Services B.V. (NL) 2005-06-15 EP claimed
US-6767671-B2 STABILITY; HEAT RESISTANCE MITSUBISHI CHEMICAL CORPORATION (JP) 2004-07-27 US claimed
WO-2004007591-A1 PROCESS FOR THE PREPARATION OF POLYORGANOSILYLATED CARBOXYLATE MONOMERS OR POLYMERS THEREOF SIGMAKALON SERVICES B.V. (NL) 2004-01-22 WO claimed
US-20020025477-A1 Non-aqueous electrolytic solution and secondary battery containing same MITSUBISHI CHEMICAL CORPORATION (JP) 2002-02-28 US claimed
EP-1172878-A2 Non-aqueous electrolytic solution and secondary battery containing same MITSUBISHI CHEMICAL CORPORATION (JP) 2002-01-16 EP claimed
EP-4608509-A1 NEW INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Institut National de la Santé et de la Recherche Médicale (FR) 2025-09-03 EP disclosed
US-20240239809-A1 THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION ARTUS THERAPEUTICS INC (US) 2024-07-18 US disclosed
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 US disclosed
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 US disclosed
US-20240217963-A1 RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-07-04 US disclosed
EP-0264183-A1 Derivatives of 5-methyl-10,11-dihydro-5H-dibenzo-(a,d) cyclohepten-5,10-imine MERCK & CO. INC. (US) 1988-04-20 EP disclosed
US-4725373-A CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS THE DOW CHEMICAL COMPANY (US) 1988-02-16 US disclosed
US-4724003-A Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines THE DOW CHEMICAL COMPANY (US) 1988-02-09 US disclosed
EP-0242289-A1 Process for the preparation of oxazinobenzothiazine 6,6-dioxide derivatives LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 1987-10-21 EP disclosed
US-4676834-A Novel compositions prepared from methyl substituted nitrogen-containing aromatic heterocyclic compounds and an aldehyde or ketone THE DOW CHEMICAL COMPANY (US) 1987-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149925-A1 PROCESS FOR PREPARING TAXOIDS FROM BACCATIN DERIVATIVES USING LEWIS ACID CATALYST TBCA, CEL, LTN1 UHRF1 1747/4885CCR1 2128/4885CCR5 1298/4885
US-20060142516-A1 Process for the preparation of polyorganosilylated carboxylate monomers or polymers thereof C1R, C9, PCBP1 UHRF1 2459/4885CCR1 267/4885CCR5 298/4885
US-20240239809-A1 THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION LIPG, FABP2, EPCAM UHRF1 3641/4885CCR1 1037/4885CCR5 1004/4885
US-12037324-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 UHRF1 4381/4885CCR1 588/4885CCR5 153/4885
US-20240217963-A1 RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF RIPK1, RIPK2, RIPK4 UHRF1 864/4885CCR1 1383/4885CCR5 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.